Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) Income from Continuing Operations (2018 - 2025)

Bicycle Therapeutics' Income from Continuing Operations history spans 8 years, with the latest figure at 204465000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 60.0% year-over-year to 204465000.0; the TTM value through Dec 2025 reached 5672000.0, down 46.57%, while the annual FY2025 figure was 5646000.0, 46.81% down from the prior year.
  • Income from Continuing Operations reached 204465000.0 in Q4 2025 per BCYC's latest filing, up from 59100000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 204465000.0 in Q4 2025 to a low of 78952000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 17284450.0, with a median of 31669500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: surged 378.84% in 2024, then tumbled 129.1% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 18022000.0 in 2021, then tumbled by 93.95% to 34954000.0 in 2022, then crashed by 31.12% to 45830000.0 in 2023, then soared by 378.84% to 127791000.0 in 2024, then skyrocketed by 60.0% to 204465000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Income from Continuing Operations are 204465000.0 (Q4 2025), 59100000.0 (Q3 2025), and 78952000.0 (Q2 2025).